Saatja: "EARS-Net" <
[email protected]>
Saaja:
[email protected],
[email protected],
[email protected], "katrien.latour" <
[email protected]>, "ivanoov" <
[email protected]>,
[email protected], "Iva Butic" <
[email protected]>, "dpieridou" <
[email protected]>,
[email protected], "Anette M. Hammerum" <
[email protected]>, "Barbara Juliane Holzknecht" <
[email protected]>, "Marliin Koolmeister" <
[email protected]>, "Kairi Tõnsau" <
[email protected]>, "Kati Räisänen" <
[email protected]>,
[email protected],
[email protected], "sylvie.maugat" <
[email protected]>,
[email protected], "Nolli" <
[email protected]>, "Michalis Polemis" <
[email protected]>,
[email protected], "Kristjan Orri Helgason" <
[email protected]>,
[email protected],
[email protected], "Errico Giulia" <
[email protected]>,
[email protected], "solvita.selderina" <
[email protected]>, "gatis.pakarna" <
[email protected]>, "Walser-Domjan Esther" <
[email protected]>, "Jekaterina Sinotova" <
[email protected]>, "Jolanta Miciuleviciene" <
[email protected]>,
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
[email protected], "gunnar.skov.simonsen" <
[email protected]>, "d.zabicka" <
[email protected]>, "Manuela Caniça" <
[email protected]>, "roxana.serban" <
[email protected]>, "Martin Sojka" <
[email protected]>, "Helena Ribič" <
[email protected]>, "baracil" <
[email protected]>,
[email protected]
Teema: For info: upcoming ECDC (DTU Food) survey of EARS-Net EQA clinical laboratories re their AST of 6 Reserve antimicrobials - EASTR (2025)
Kuupäev: 2025-03-19 13:35
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
To: National EQA coordinators for the EARS-Net EQA, 2025
Cc: National Focal Points for AMR; National Coordinators of Coordinating
Competent Bodies
Dear colleagues,
Thank you for your activities for the EARS-Net EQA, following your
designation as the national contact for the 2025 EQA by your National Focal
Point for AMR.
For your information:
ECDC will soon send a survey to the nationally-designated contacts in
clinical laboratories that were invited to participated in EARS-Net EQAs in
2021–2024, in all 30 EU/EEA countries. The survey will be distributed to
each laboratory by the ECDC contractor for the EARS-Net EQAs in 2021-2024,
i.e. the National Food Institute, Technical University of Denmark (DTU
Food).
Here is more information about the survey:
The survey is named the ‘ECDC EARS-Net survey of clinical laboratories
regarding antimicrobial susceptibility testing of the WHO AWaRe Reserve
antimicrobials for selected Gram-negative pathogens, 2025’ (EASTR (2025)).
Its purpose is to gather information regarding these pathogen-antimicrobial
combinations, to guide the appropriate use of EARS-Net AMR surveillance data
for public health purposes, and, importantly, to map the limitations of
these data.
EASTR (2025) collects information related to antimicrobial susceptibility
testing (AST) methods for four pathogens (Escherichia coli, Klebsiella
pneumonia, Acinetobacter species, and Pseudomonas aeruginosa) and six
antibiotics from the Reserve group of the WHO AwaRe classification (2023).
These six antibiotics were newly added, in 2024, to the
<https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data>
ECDC EARS-Net AMR surveillance
<https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-amr-reporting-protocol-2024>
protocol (i.e. ceftazidime-avibactam, cefiderocol, ceftolozane-tazobactam,
imipenem-relebactam and meropenem-vaborbactam) and/or to the EUCAST clinical
breakpoints (i.e. aztreonam-avibactam, which had breakpoints
<https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Addenda/Aztreonam-avibactam_addendum_22_May_2024.pdf>
published on 22 May 2024 and included in
<https://www.eucast.org/clinical_breakpoints> breakpoints table 15.0).
EASTR (2025) was developed as a collaboration between ECDC and DTU Food. The
survey was discussed with national attendees of the EARS-Net Network meeting
in June 2024 and at EARS-Net Disease Network Coordination Committee (DNCC)
meetings in 2023–2025. In Q4 2024, the survey was piloted in 7 laboratories
in 7 countries.
DTU Food will distribute the survey to laboratories, via a hyperlink in an
email, using their EQA webtool. Following the national feedback received at
the Network meeting, DTU Food has provided translations of the survey into
European languages, including the 24 official EU languages, on its webpage
( <https://www.food.dtu.dk/english/topics/antimicrobial-resistance/ears-net>
https://www.food.dtu.dk/english/topics/antimicrobial-resistance/ears-net).
The pilot indicated that it should take about 60 minutes to complete the
survey.
ECDC currently plans to present some key findings from EASTR (2025) in the
ECDC Annual Epidemiological Report (AER) for AMR in 2025, because the
previous and upcoming EARS-Net surveillance protocol permit reporting of a
subset of these new antimicrobial data. Subsequently, ECDC plans to report
on all EASTR (2025) data. If ECDC drafts a public output that includes
national-level EASTR (2025) data, the standard practice is to send it to
countries for comments prior to publication. Outputs will not present
laboratory identifiers.
Please don’t hesitate to contact us if you have any questions (
<mailto:
[email protected]>
[email protected]), or you are
welcome to contact DTU Food directly ( <mailto:
[email protected]>
[email protected]).
Thank you, in advance, for your interest in this topic area.
Hanna Merk, Pete Kinross (ECDC)
and Ana Rita Rebelo, Birgitte Helwigh (DTU Food)
European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00
<https://www.ecdc.europa.eu/> www.ecdc.europa.eu
Follow ECDC on:
<http://www.facebook.com/ECDC.EU>
<https://bsky.app/profile/ecdc.europa.eu>
<http://www.linkedin.com/company/ecdc>
<http://www.youtube.com/user/ECDCchannel>
<https://www.instagram.com/ecdc.eu>
<https://www.threads.net/@ecdc.eu>
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly
requested, to, consecutively, refrain from disclosing its content to any
third party, delete it and inform its sender of the erroneous transmittal.